[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378226-105":59,"doc-detail-378226-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mucocutaneous-findings-in-hematolymphoid-neoplasms-an-observational-study","Mucocutaneous Findings in Hematolymphoid Neoplasms - An Observational Study","","Cutaneous manifestations of hematological neoplasms are categorized as direct infiltration, paraneoplastic conditions, and treatment-related effects of hematologic cancer therapies. This observational cross-sectional study assessed the frequency and patterns of mucocutaneous findings in 172 patients with hematolymphoid neoplasms and those receiving chemotherapy. Malignancy-related lesions occurred in 15.6%, while chemotherapy-associated nail changes and infections, alopecia, hyperpigmentation, and drug-specific associations were documented, supporting early recognition to reduce treatment morbidity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mucocutaneous-findings-in-hematolymphoid-neoplasms-an-observational-study/378226/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mucocutaneous-findings-in-hematolymphoid-neoplasms-an-observational-study/378226.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were mucocutaneous manifestations categorized in the study?","Question",{"text":112,"@type":113},"They were divided into malignancy-associated manifestations and chemotherapy-drugs-associated manifestations. The introduction further describes three broad categories: direct infiltration, paraneoplastic conditions, and treatment-related cutaneous effects and immunosuppression-related infections.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of patients had malignancy-related mucocutaneous manifestations?",{"text":117,"@type":113},"Out of 172 patients, 15.6% (27/172) had malignancy-related mucocutaneous manifestations. Among these, 4.6% (8/172) had direct infiltration and 11% (19/172) had paraneoplastic manifestations.",{"name":119,"@type":110,"acceptedAnswer":120},"Which chemotherapy-related mucocutaneous findings were most common?",{"text":121,"@type":113},"The most common chemotherapy-related finding was nail changes, occurring in 47.1% (81/172). Transverse melanonychia was the most common nail change, reported in 20.9%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},378226,1790672582,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Article  \nMucocutaneous Findings in Hematolymphoid Neoplasms: An Observational Study  \nAbstract  \nBackground: Cutaneous manifestations of hematological neoplasms can be divided into three broad categories – direct infiltration, paraneoplastic conditions, and those due to the treatment of hematological cancers. Objectives: To study the frequency and patterns of mucocutaneous manifestations in patients with hematolymphoid neoplasms and those due to chemotherapy. Materials and Methods: This was an observational study done with 172 patients. Categorization of mucocutaneous manifestations was done into malignancy‑associated and chemotherapeutic drugs‑associated and data was analyzed. Results: Out of a total of 172 patients, 15.6%(27/172) had malignancy‑related mucocutaneous manifestations. Among these, 4.6%(8/172) had direct infiltration of malignant cells into the skin and 11%(19/172) had paraneoplastic manifestations. The most common chemotherapy‑related mucocutaneous manifestations were nail changes – 47.1%(81/172), of which transverse melanonychia was the most common (20.9%) . About 44.2%(76/172) had a cutaneous infection, the commonest of which was a fungal infection (15.1%) . Chemotherapy‑induced alopecia was noted in 46.5%(80/172) and found to be significantly associated with cytarabine, daunorubicin, doxorubicin, methotrexate, and vincristine. Cutaneous hyperpigmentation was found tobe significantly associated with cytarabine, doxorubicin, and vincristine. Conclusion: Mucocutaneous manifestations cause additional discomfort to a patient undergoing chemotherapy. Early recognition and timely and appropriate management facilitate symptom control and prevent treatment‑related morbidity. A multidisciplinary approach involving hemato‑oncologists and dermatologists can help achieve this target.  \nKeywords: Chemotherapy, hematolymphoid, mucocutaneous, neoplasms   \nIntroduction  \nCutaneous manifestations of hematological neoplasms can be divided into three broad categories:[1] (a) Direct infiltration of skin with malignant cells or their products (e.g., paraproteins) (b) Paraneoplastic conditions or dermatological syndromes associated with underlying malignancy (c) Treatment‑related cutaneous manifestations, mainly adverse effects of chemotherapeutic agents and infections secondary to immunosuppression. Diagnosis of hematological malignancy is usually established before skin lesions appear (e.g., leukemia cutis) or skin lesions maybe the presenting feature (e.g., sweet’s syndrome and purpura) . Given the varying presentations, mucocutaneous findings associated with hematolymphoid neoplasms can pose diagnostic challenges for hemato‑oncologists and dermatologists.  \nThis is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.  \n[For reprints contact:](For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com)[ WKHLRPMedknow_reprints@wolterskluwer.com](For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com)  \nIn this study, we attempt to describe the cutaneous findings in patients with various hematological malignancies and those due to chemotherapy regimens.  \nMaterials and Methods  \nThis cross‑sectional study was conducted in the department of dermatology and hematology between September 2019 and February 2021. The study protocol (No. 290/IEC/PGM/2019) was approved by the Institutional Ethics Committee. A confirmed case of hematolymphoid neoplasm of any age and gender on chemotherapy regimens as per WHO guidelines[2] with mucocutaneous involvement was included after written consent. Patients with cutaneous findings secondary to thrombocytopenia or after blood product transfusion were excluded. Clinical and laboratory details were entered in a pre‑","cbCaidVnSN4DKKvc","https://ap.wps.com/l/cbCaidVnSN4DKKvc","pdf",1888997,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results","[{\"question\":\"How were mucocutaneous manifestations categorized in the study?\",\"answer\":\"They were divided into malignancy-associated manifestations and chemotherapy-drugs-associated manifestations. The introduction further describes three broad categories: direct infiltration, paraneoplastic conditions, and treatment-related cutaneous effects and immunosuppression-related infections.\"},{\"question\":\"What proportion of patients had malignancy-related mucocutaneous manifestations?\",\"answer\":\"Out of 172 patients, 15.6% (27/172) had malignancy-related mucocutaneous manifestations. Among these, 4.6% (8/172) had direct infiltration and 11% (19/172) had paraneoplastic manifestations.\"},{\"question\":\"Which chemotherapy-related mucocutaneous findings were most common?\",\"answer\":\"The most common chemotherapy-related finding was nail changes, occurring in 47.1% (81/172). Transverse melanonychia was the most common nail change, reported in 20.9%.\"}]","Mucocutaneous Findings in Hematolymphoid Neoplasms - An Observational Study | PDF",1790229032,18]